<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02192684</url>
  </required_header>
  <id_info>
    <org_study_id>5U01HL108647-04</org_study_id>
    <nct_id>NCT02192684</nct_id>
  </id_info>
  <brief_title>Obesity, Sleep Apnea, and Insulin Resistance</brief_title>
  <official_title>Interfacing Adiposity, Sleep Apnea, and Insulin Resistance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Obstructive sleep apnea (OSA) and type 2 diabetes confer increasing economic, social, and
      public health burdens in the United States. That these diseases appear to co-exist and
      together increase one's risk of cardiovascular disease renders investigation into their
      shared pathophysiology even more urgent. Investigators will assess prevalence of insulin
      resistance, a precursor to diabetes, among overweight patients with OSA. Among those at
      highest risk of diabetes, investigators will randomize participants to pioglitazone or
      placebo to see the efficacy of the intervention on improving OSA, insulin resistance, and/or
      insulin secretion. In a separate intervention, investigators will evaluate the
      cardiometabolic benefits of continuous positive airway pressure (CPAP) for 12 weeks in
      patients with OSA. Investigators will also study subjects from the community without known
      sleep apnea, and assess whether insulin-resistant individuals are at risk for sleep apnea
      using clinical screening questionnaires.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Apnea-hypopnea Index (AHI) Outcome Measure in Response to Pioglitazone or Placebo</measure>
    <time_frame>8 weeks</time_frame>
    <description>To evaluate the effects of pioglitazone versus placebo on AHI in patients with OSA.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Insulin Sensitivity</condition>
  <condition>Obstructive Sleep Apnea</condition>
  <arm_group>
    <arm_group_label>pioglitazone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>pioglitazone 45 mg, oral, daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, one pill daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pioglitazone</intervention_name>
    <description>45 mg daily Insulin sensitizing</description>
    <arm_group_label>pioglitazone</arm_group_label>
    <other_name>actos</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Compare with pioglitazone</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy Individuals

          -  Age 30-70 years old

          -  BMI- 25-40 kg/m2

          -  Must meet criteria for obstructive sleep apnea by overnight in-laboratory
             polysomnography

        Exclusion Criteria:

          -  Any significant co-morbidities, such as diabetes, active heart, kidney, liver
             diseases, or active or history of bladder cancer.

          -  Must not have previously received treatment for OSA, including CPAP.

          -  Must not be receiving any medications intended for weight loss, or those known to
             influence insulin sensitivity.

          -  Pregnancy/lactation is also an exclusion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerald M Reaven, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 7, 2014</study_first_submitted>
  <study_first_submitted_qc>July 16, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 17, 2014</study_first_posted>
  <results_first_submitted>November 18, 2016</results_first_submitted>
  <results_first_submitted_qc>March 14, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 21, 2017</results_first_posted>
  <last_update_submitted>March 14, 2017</last_update_submitted>
  <last_update_submitted_qc>March 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Gerald M Reaven</investigator_full_name>
    <investigator_title>Professor Emeritus</investigator_title>
  </responsible_party>
  <keyword>obstructive sleep apnea</keyword>
  <keyword>insulin sensitivity</keyword>
  <keyword>cardiovascular risk</keyword>
  <keyword>positive airway pressure therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
    <mesh_term>Hypersensitivity</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Pioglitazone</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Dates: July 10 2010 - March 2014</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Pioglitazone</title>
          <description>pioglitazone 45 mg, oral, daily
Pioglitazone: 45 mg daily Insulin sensitizing</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo, one pill daily
placebo: Compare with pioglitazone</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Pioglitazone</title>
          <description>pioglitazone 45 mg, oral, daily
Pioglitazone: 45 mg daily Insulin sensitizing</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo, one pill daily
placebo: Compare with pioglitazone</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="45"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51" spread="11"/>
                    <measurement group_id="B2" value="50" spread="12"/>
                    <measurement group_id="B3" value="50.5" spread="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Changes in sleep measure</title>
          <description>apnea-hypopnea index (AHI) events per hour</description>
          <units>Apnea-hypopnea index (AHI) events/hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.9" spread="11.9"/>
                    <measurement group_id="B2" value="40.8" spread="12.3"/>
                    <measurement group_id="B3" value="38.9" spread="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Insulin Sensitivity</title>
          <description>Steady-state plasma glucose (mmol/L)</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11.9" spread="2.1"/>
                    <measurement group_id="B2" value="12.3" spread="2.0"/>
                    <measurement group_id="B3" value="12.1" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Apnea-hypopnea Index (AHI) Outcome Measure in Response to Pioglitazone or Placebo</title>
        <description>To evaluate the effects of pioglitazone versus placebo on AHI in patients with OSA.</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pioglitazone</title>
            <description>pioglitazone 45 mg, oral, daily
Pioglitazone: 45 mg daily Insulin sensitizing</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo, one pill daily
placebo: Compare with pioglitazone</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Apnea-hypopnea Index (AHI) Outcome Measure in Response to Pioglitazone or Placebo</title>
          <description>To evaluate the effects of pioglitazone versus placebo on AHI in patients with OSA.</description>
          <units>AHI events/hour</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.8" lower_limit="21" upper_limit="49"/>
                    <measurement group_id="O2" value="34.4" lower_limit="18" upper_limit="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Pioglitazone</title>
          <description>pioglitazone 45 mg, oral, daily
Pioglitazone: 45 mg daily Insulin sensitizing</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo, one pill daily
placebo: Compare with pioglitazone</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>Other</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>weight gain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Unrecognized adverse effect of pioglitazone could have obviated a beneficial effect of enhanced insulin sensitivity on OSA related sleep measures.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Gerald Reaven</name_or_title>
      <organization>Stanford Universtiy</organization>
      <phone>650-724-3416</phone>
      <email>greaven@stanford.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

